Alphatec Competitors

Abbott Laboratories (NYSE:ABT) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Abbott Laboratories and Alphatec's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Abbott Laboratories and Alphatec, as reported by MarketBeat.

Abbott Laboratories presently has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Abbott Laboratories.

Valuation and Earnings

This table compares Abbott Laboratories and Alphatec's revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

63.9% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

Abbott Laboratories beats Alphatec on 9 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Medtronic and Alphatec's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Medtronic and Alphatec, as reported by MarketBeat.

Medtronic presently has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Medtronic.

Valuation and Earnings

This table compares Medtronic and Alphatec's revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

Medtronic beats Alphatec on 10 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Stryker and Alphatec's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Stryker and Alphatec, as reported by MarketBeat.

Stryker presently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Stryker.

Valuation and Earnings

This table compares Stryker and Alphatec's revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Summary

Stryker beats Alphatec on 10 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Alphatec (NASDAQ:ATEC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for Intuitive Surgical and Alphatec, as reported by MarketBeat.

Intuitive Surgical presently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Alphatec has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Given Alphatec's stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Intuitive Surgical.

Institutional and Insider Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 31.3% of Alphatec shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 28.2% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Intuitive Surgical and Alphatec's net margins, return on equity and return on assets.

Volatility & Risk

Intuitive Surgical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Valuation and Earnings

This table compares Intuitive Surgical and Alphatec's revenue, earnings per share and valuation.

Intuitive Surgical has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Intuitive Surgical beats Alphatec on 10 of the 14 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alphatec and Becton, Dickinson and, as reported by MarketBeat.com.

Alphatec presently has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's higher possible upside, analysts plainly believe Becton, Dickinson and is more favorable than Alphatec.

Institutional & Insider Ownership

31.3% of Alphatec shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 28.2% of Alphatec shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Alphatec and Becton, Dickinson and's net margins, return on equity and return on assets.

Risk and Volatility

Alphatec has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alphatec and Becton, Dickinson and's revenue, earnings per share and valuation.

Becton, Dickinson and has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and beats Alphatec on 11 of the 15 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Alphatec and Edwards Lifesciences, as reported by MarketBeat.com.

Alphatec presently has a consensus price target of $12.1667, suggesting a potential upside of 15.32%. Edwards Lifesciences has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Given Alphatec's stronger consensus rating and higher possible upside, analysts plainly believe Alphatec is more favorable than Edwards Lifesciences.

Institutional & Insider Ownership

31.3% of Alphatec shares are held by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are held by institutional investors. 28.2% of Alphatec shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Alphatec and Edwards Lifesciences' net margins, return on equity and return on assets.

Risk and Volatility

Alphatec has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alphatec and Edwards Lifesciences' revenue, earnings per share and valuation.

Edwards Lifesciences has higher revenue and earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Edwards Lifesciences beats Alphatec on 10 of the 14 factors compared between the two stocks.